Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype

Pharmacol Rep. 2005 Jan-Feb;57(1):124-7.

Abstract

Serotonin transporter promoter length polymorphism (5-HTTLPR) has been implicated in the pathogenesis of mood disorders and in the therapeutic response to serotonergic drugs. In this study, the 5-HTTLPR was estimated in 67 patients with bipolar mood disorder, receiving lithium carbonate for prophylactic purposes for the period of more than 5 years (mean 15 years). The patients were divided into excellent responders (n = 18), partial responders (n = 35) and poor responders (n = 14). In lithium non-responders, the genotype s/s and the allele s was significantly more frequent than in excellent and partial responders. The obtained results are discussed in view of other studies showing an association of S genotype with worse response to serotonergic drugs. A supposition is made that prophylactic management of bipolar illness can be optimized by defining 5-HTTLPR genotype.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antidepressive Agents / therapeutic use*
  • Bipolar Disorder / drug therapy*
  • Bipolar Disorder / genetics
  • Female
  • Genotype
  • Humans
  • Lithium Carbonate / therapeutic use*
  • Male
  • Membrane Glycoproteins / drug effects
  • Membrane Glycoproteins / genetics*
  • Membrane Transport Proteins / drug effects
  • Membrane Transport Proteins / genetics*
  • Middle Aged
  • Nerve Tissue Proteins / drug effects
  • Nerve Tissue Proteins / genetics*
  • Pharmacogenetics
  • Serotonin Plasma Membrane Transport Proteins

Substances

  • Antidepressive Agents
  • Membrane Glycoproteins
  • Membrane Transport Proteins
  • Nerve Tissue Proteins
  • SLC6A4 protein, human
  • Serotonin Plasma Membrane Transport Proteins
  • Lithium Carbonate